Drug safety evaluation of dronedarone in atrial fibrillation

Gaetano M. De Ferrari, Veronica Dusi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction: Dronedarone was developed with the intent of replicating the antiarrhythmic effects of amiodarone, while minimizing its side effects. Areas covered: Side effects reported in eight randomized clinical trials are discussed, comparing dronedarone and placebo (DAFNE, EURIDIS, ADONIS, ERATO, ANDROMEDA, ATHENA, PALLAS, total number of patients treated with dronedarone 5347), or dronedarone and amiodarone (DIONYSOS, total number of patients treated with dronedarone 249). Expert opinion: The results of the first trials, including ATHENA, set high expectations by suggesting that dronedarone may decrease the risk of hospitalization (and even cardiovascular mortality) among patients with paroxysmal and persistent atrial fibrillation (AF), and that it could be regarded as an easy-to-use drug that could be prescribed by general practitioners; unfortunately, dronedarone has not met these expectations. Dronedarone may increase mortality and heart failure hospitalization in patients with advanced NYHA class and in patients with permanent AF, preventing its use in these settings. In addition to gastrointestinal side effects that may lead to discontinuation in 5 10% of patients, dronedarone may induce very rare but severe liver and lung toxicity. Despite these limitations and its relatively limited antiarrhythmic potency, dronedarone may still be a useful drug for well-selected patients.

Original languageEnglish
Pages (from-to)1023-1045
Number of pages23
JournalExpert Opinion on Drug Safety
Volume11
Issue number6
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Drug Evaluation
Atrial Fibrillation
Safety
Amiodarone
Adonis
Hospitalization
dronedarone
Mortality
Expert Testimony
Pharmaceutical Preparations
General Practitioners
Randomized Controlled Trials
Heart Failure
Placebos
Lung

Keywords

  • Amiodarone
  • Antiarrhythmic therapy
  • Atrial fibrillation
  • Clinical trials
  • Dronedarone
  • Heart failure
  • Safety
  • SR33589

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Drug safety evaluation of dronedarone in atrial fibrillation. / De Ferrari, Gaetano M.; Dusi, Veronica.

In: Expert Opinion on Drug Safety, Vol. 11, No. 6, 11.2012, p. 1023-1045.

Research output: Contribution to journalArticle

@article{acfa3cee04234a49890a75334b2d83b5,
title = "Drug safety evaluation of dronedarone in atrial fibrillation",
abstract = "Introduction: Dronedarone was developed with the intent of replicating the antiarrhythmic effects of amiodarone, while minimizing its side effects. Areas covered: Side effects reported in eight randomized clinical trials are discussed, comparing dronedarone and placebo (DAFNE, EURIDIS, ADONIS, ERATO, ANDROMEDA, ATHENA, PALLAS, total number of patients treated with dronedarone 5347), or dronedarone and amiodarone (DIONYSOS, total number of patients treated with dronedarone 249). Expert opinion: The results of the first trials, including ATHENA, set high expectations by suggesting that dronedarone may decrease the risk of hospitalization (and even cardiovascular mortality) among patients with paroxysmal and persistent atrial fibrillation (AF), and that it could be regarded as an easy-to-use drug that could be prescribed by general practitioners; unfortunately, dronedarone has not met these expectations. Dronedarone may increase mortality and heart failure hospitalization in patients with advanced NYHA class and in patients with permanent AF, preventing its use in these settings. In addition to gastrointestinal side effects that may lead to discontinuation in 5 10{\%} of patients, dronedarone may induce very rare but severe liver and lung toxicity. Despite these limitations and its relatively limited antiarrhythmic potency, dronedarone may still be a useful drug for well-selected patients.",
keywords = "Amiodarone, Antiarrhythmic therapy, Atrial fibrillation, Clinical trials, Dronedarone, Heart failure, Safety, SR33589",
author = "{De Ferrari}, {Gaetano M.} and Veronica Dusi",
year = "2012",
month = "11",
doi = "10.1517/14740338.2012.722994",
language = "English",
volume = "11",
pages = "1023--1045",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Drug safety evaluation of dronedarone in atrial fibrillation

AU - De Ferrari, Gaetano M.

AU - Dusi, Veronica

PY - 2012/11

Y1 - 2012/11

N2 - Introduction: Dronedarone was developed with the intent of replicating the antiarrhythmic effects of amiodarone, while minimizing its side effects. Areas covered: Side effects reported in eight randomized clinical trials are discussed, comparing dronedarone and placebo (DAFNE, EURIDIS, ADONIS, ERATO, ANDROMEDA, ATHENA, PALLAS, total number of patients treated with dronedarone 5347), or dronedarone and amiodarone (DIONYSOS, total number of patients treated with dronedarone 249). Expert opinion: The results of the first trials, including ATHENA, set high expectations by suggesting that dronedarone may decrease the risk of hospitalization (and even cardiovascular mortality) among patients with paroxysmal and persistent atrial fibrillation (AF), and that it could be regarded as an easy-to-use drug that could be prescribed by general practitioners; unfortunately, dronedarone has not met these expectations. Dronedarone may increase mortality and heart failure hospitalization in patients with advanced NYHA class and in patients with permanent AF, preventing its use in these settings. In addition to gastrointestinal side effects that may lead to discontinuation in 5 10% of patients, dronedarone may induce very rare but severe liver and lung toxicity. Despite these limitations and its relatively limited antiarrhythmic potency, dronedarone may still be a useful drug for well-selected patients.

AB - Introduction: Dronedarone was developed with the intent of replicating the antiarrhythmic effects of amiodarone, while minimizing its side effects. Areas covered: Side effects reported in eight randomized clinical trials are discussed, comparing dronedarone and placebo (DAFNE, EURIDIS, ADONIS, ERATO, ANDROMEDA, ATHENA, PALLAS, total number of patients treated with dronedarone 5347), or dronedarone and amiodarone (DIONYSOS, total number of patients treated with dronedarone 249). Expert opinion: The results of the first trials, including ATHENA, set high expectations by suggesting that dronedarone may decrease the risk of hospitalization (and even cardiovascular mortality) among patients with paroxysmal and persistent atrial fibrillation (AF), and that it could be regarded as an easy-to-use drug that could be prescribed by general practitioners; unfortunately, dronedarone has not met these expectations. Dronedarone may increase mortality and heart failure hospitalization in patients with advanced NYHA class and in patients with permanent AF, preventing its use in these settings. In addition to gastrointestinal side effects that may lead to discontinuation in 5 10% of patients, dronedarone may induce very rare but severe liver and lung toxicity. Despite these limitations and its relatively limited antiarrhythmic potency, dronedarone may still be a useful drug for well-selected patients.

KW - Amiodarone

KW - Antiarrhythmic therapy

KW - Atrial fibrillation

KW - Clinical trials

KW - Dronedarone

KW - Heart failure

KW - Safety

KW - SR33589

UR - http://www.scopus.com/inward/record.url?scp=84867830357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867830357&partnerID=8YFLogxK

U2 - 10.1517/14740338.2012.722994

DO - 10.1517/14740338.2012.722994

M3 - Article

C2 - 22971242

AN - SCOPUS:84867830357

VL - 11

SP - 1023

EP - 1045

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -